IP Verse

Crispr Therapeutics competitive analysis

Latest publications and patents of Crispr Therapeutics New

Explore the latest publications and patents granted to Crispr Therapeutics, showcasing their recent innovations and technological advancements.

Latest oppositions filed by Crispr Therapeutics

Explore patent oppositions filed by Crispr Therapeutics against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3603679
Rna-Guideded Transcriptional RegulationPRESIDENT AND FELLOWS OF HARVARD COLLEGEAug 11, 2022
EP3733847
Composition For Cleaving A Target Dna Comprising A Guide Rna Specific For The Target Dna And Cas Protein-Encoding Nucleic Acid Or Cas Protein, And Use ThereofTOOLGEN INCORPORATEDJun 2, 2022
EP3327127
Delivery, Engineering And Optimization Of Systems, Methods And Compositions For Sequence Manipulation And Therapeutic ApplicationsMASSACHUSETTS INSTITUTE OF TECHNOLOGYApr 7, 2021
EP3011031
Delivery And Use Of The Crispr-Cas Systems, Vectors And Compositions For Hepatic Targeting And TherapyMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 13, 2020
EP3252160
Crispr-Cas Component Systems, Methods And Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYOct 29, 2020
EP3144390
Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYMar 19, 2020
EP3064585
Engineering And Optimization Of Improved Systems, Methods And Enzyme Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
EP3494997
Inducible Dna Binding Proteins And Genome Perturbation Tools And Applications ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 10, 2020
EP2940140
Engineering Of Systems, Methods And Optimized Guide Compositions For Sequence ManipulationMASSACHUSETTS INSTITUTE OF TECHNOLOGYNov 5, 2019
EP2931892
Methods, Models, Systems, And Apparatus For Identifying Target Sequences For Cas Enzymes Or Crispr-Cas Systems For Target Sequences And Conveying Results ThereofMASSACHUSETTS INSTITUTE OF TECHNOLOGYFeb 28, 2019

Latest PTAB cases involving Crispr Therapeutics

Discover the latest PTAB cases involving Crispr Therapeutics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Crispr Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
CRISPR THERAPEUTICS12 - - - Highly Aggressive
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - 72 - 16Non-Active
PRESIDENT AND FELLOWS OF HARVARD COLLEGE - 83 - 8Non-Active
THE BROAD INSTITUTE - 68 - 1Non-Active